No published human studies have tested CJC-1295 or ipamorelin for effects on fertility, sperm quality, or reproductive hormones. However, there is a significant and truly well-documented body of separate research on how growth hormone itself interacts with the reproductive system. Since these peptides work by elevating growth hormone, these broader studies provide critical, albeit indirect, context for understanding what might theoretically be at play.
CJC-1295 and ipamorelin fertility
Growth hormone has a well-established, albeit secondary, role in human reproduction. This has been studied for decades, primarily in the context of growth hormone deficiency and infertility treatments, rather than growth hormone-releasing peptides like CJC-1295 or ipamorelin specifically. A comprehensive 2023 review, examining the effects of growth hormone on adult human gonads, described something interesting. Growth hormone receptors are present in both testes and ovaries. Growth hormone may influence gonad sensitivity to the reproductive hormones that directly control fertility, specifically FSH and LH. It does this largely by working in conjunction with IGF-1, rather than acting as a primary driver of reproductive function itself [1]. This same review discussed how growth hormone supplementation has been explored as an adjunctive therapy in specific infertility treatment contexts, for both men and women. This typically involved individuals who already had a documented growth hormone deficiency, rather than individuals with normal growth hormone levels seeking fertility enhancement [1].
It is important to understand what this body of research says and what it does not say. This is research on growth hormone itself, usually administered directly, in populations specifically chosen because they had a hormonal deficiency. It does not include CJC-1295 or ipamorelin. No study has tested whether raising growth hormone indirectly through these growth hormone-releasing peptides in people without a growth hormone deficiency causes any comparable effect on fertility.
CJC-1295 and Ipamorelin and female fertility
Regarding specific effects on female fertility, the same 2023 review described a documented role for growth hormone in ovarian function. This includes its impact on ovarian follicle development, ovarian hormone production, and the presence of growth hormone receptors on cells throughout the female reproductive tract [1]. Separate reviews on the broader reproductive physiology of growth hormone have described its use in certain assisted reproduction settings. Growth hormone has been investigated as a supplement aimed at improving oocyte quality and treatment response, in specific patient populations undergoing fertility treatments. As for ipamorelin specifically, there is one notable animal study. A study in tilapia fish examined the effects of a ghrelin agonist, ipamorelin acetate, on the reproductive axis. It found that administration led to an increased number of developing reproductive cells, along with elevated luteinizing hormone and a related sex steroid hormone in this species [2].
This is a genuine discovery worth noting. However, it comes from a study on fish, which represents a significant evolutionary and physiological distance from human female reproductive biology. No comparable study has been conducted on mammals or humans specifically using ipamorelin.
Regarding menopause specifically, no studies identified in this series have analyzed CJC-1295 or ipamorelin in connection with hormonal changes or menopausal symptoms. This represents a true and complete evidentiary gap, not an area with even preliminary findings.
CJC-1295 and Ipamorelin and male fertility
Human studies specifically linking growth hormone with male fertility offer slightly more significant evidence than on the female side. However, it is important to note that these studies concern growth hormone itself, not CJC-1295 or ipamorelin. A notable human clinical trial published in Fertility and Sterility analyzed growth hormone treatment in men with subfertility who were identified as having impaired growth hormone response. It found that 12 weeks of growth hormone treatment was associated with a significant increase in sperm motility in these men. Estradiol, testosterone, prolactin, FSH, and LH levels remained unchanged throughout the study [3]. This is a significant and directly relevant human finding. However, it is important to be precise about what it establishes and what it does not. It involved direct administration of growth hormone in a specific population already identified as having reduced growth hormone responsiveness. It did not test a growth hormone secretagogue such as CJC-1295 or ipamorelin. It also did not involve men with normal baseline growth hormone levels.
Regarding ipamorelin specifically, its original pharmacological characterization involved testing in animal models in pigs. This testing demonstrated that the compound, along with related growth hormone secretagogues tested at the time, did not significantly affect FSH, LH, prolactin, or TSH levels. This suggests a degree of hormonal selectivity specifically for the growth hormone pathway, rather than broad interference with other reproductively relevant hormones in this animal model [4].
This is a calming signal at the animal pharmacology level. However, it is not the same as a dedicated study of fertility or sperm quality in humans. No such study of CJC-1295 or ipamorelin in men has been published.
Limitations of current evidence
The general picture here is one of relevant, albeit indirect, evidence. There is solid clinical data in humans linking growth hormone itself to sperm motility and reproductive hormone stability in specific populations [1], [3]. Animal studies concerning ipamorelin specifically suggest it may not widely disrupt other reproductive hormones, at least in one species tested [4]. There is also one study in fish demonstrating effects on reproductive cell development [2].
None of these, however, add up to direct evidence that CJC-1295 or ipamorelin affects human fertility, sperm quality, or the balance of reproductive hormones in men or women. No dedicated human study for either peptide for this purpose has been conducted.
Disclaimer
This content is for educational and informational purposes only and should not be construed as medical advice, diagnosis, or treatment recommendation. CJC-1295 and Ipamorelin remain research compounds and are not approved by the FDA or the European Medicines Agency for any medical use, whether used alone or in combination. No published human trials have tested either compound for effects on fertility, sperm quality, or reproductive hormones. Any individuals experiencing fertility concerns should consult with a qualified healthcare professional or fertility specialist for evidence-based evaluation and treatment options.
References
Zhou, X.-Y., Ma, J.-N., Shen, Y.-Y., Xie, X.-R., & Ren, W. (2023). Effects of growth hormone on adult human gonads: Action on reproduction and sexual function. International Journal of Endocrinology, 2023, Article 7492696. https://doi.org/10.1155/2023/7492696
Gouda, M., & Ganesh, C. B. (2024). The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Mozambique tilapia. Animal Reproduction Science, 268, Article 107550. https://doi.org/10.1016/j.anireprosci.2024.107550
[3] Ovesen, P., Jørgensen, J. O., Ingerslev, J., Ho, K. K., Ørskov, H., & Christiansen, J. S. (1996). Growth hormone treatment of subfertile males. Fertility and Sterility, 66(2), 292–298. https://doi.org/10.1016/S0015-0282(16)58456-8
[4] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552